Genmab Wraps Up Leveraged Finance’s Biggest M&A Deal Since April

Danish biotech Genmab A/S completed a $4.5 billion acquisition financing—the largest U.S. leveraged-finance M&A deal since April—by arranging a $2.0 billion leveraged loan priced at SOFR plus 300 basis points and issuing $2.5 billion of high-yield notes in two tranches yielding 6.25% and 7.25%, according to a person familiar with the matter. The deal highlights sustained demand for leveraged loan and junk-bond funding for M&A activity and provides a fresh pricing reference in the high-yield market, though the report did not detail lender syndication or longer-term covenant structures.

Analysis

Genmab A/S completed a $4.5 billion acquisition financing package, consisting of a $2.0 billion leveraged loan priced at SOFR plus 300 basis points and $2.5 billion of high-yield notes issued in two tranches yielding 6.25% and 7.25%, marking the largest U.S. leveraged-finance M&A deal since April. The size and pricing establish a fresh market reference for both the leveraged-loan and high-yield sectors and signal continuing investor demand for M&A funding despite higher rate environments. The coupon levels imply a meaningful cost of capital for the transaction that will influence deal economics and sponsor returns; issuance at mid-6% and 7.25% indicates investors are willing to take credit risk for spread pickup but still demand material compensation. The report did not disclose lender syndication, covenant packages or longer-term amortization and refinancing mechanics, creating execution and credit-monitoring risks; secondary trading and covenant detail will be critical next data points to assess relative value and issuer risk in the biotech and broader leveraged-credit complex.

Key Decisions for Investors

• Use this transaction as an immediate pricing reference for leveraged loan and high-yield credit — consider opportunistic exposure to short-dated high-yield or loan paper if spreads reprice tighter toward the Genmab levels,
• Exercise caution on equity positions in heavily leveraged biotech deals until covenant and syndication terms are disclosed; it may be prudent to hedge downside or reduce position size given the higher cost of capital,
• Monitor secondary-market trading in the Genmab tranches and other new-issue concessions as leading indicators of liquidity; if market demand softens, tighten stop-loss or hedging thresholds for credit-sensitive holdings,
• Watch for follow-on M&A financings using this deal as a benchmark; a pickup in similar-sized issuance would signal sustained liquidity and could justify selective overweight in liquid high-yield and syndicated loan strategies.